# Xenon Pharmaceuticals (stock symbol: XENE) Logo in transparent PNG and SVG formats

## Xenon Pharmaceuticals Logo large

### Xenon Pharmaceuticals Logo large Download PNG (23.13 KB)

![Xenon Pharmaceuticals Logo large Download PNG (23.13 KB)](/img/orig/XENE_BIG-62553377.png)

### Xenon Pharmaceuticals Logo large Download SVG (5.18 KB)

![Xenon Pharmaceuticals Logo large Download SVG (5.18 KB)](/img/orig/XENE_BIG-19aacf6e.svg)

## Xenon Pharmaceuticals Logo icon format

### Xenon Pharmaceuticals Logo icon format Download PNG (24.72 KB)

![Xenon Pharmaceuticals Logo icon format Download PNG (24.72 KB)](/img/orig/XENE-b7815914.png)

### Xenon Pharmaceuticals Logo icon format Download SVG (2.24 KB)

![Xenon Pharmaceuticals Logo icon format Download SVG (2.24 KB)](/img/orig/XENE-4a1b3da6.svg)

## Xenon Pharmaceuticals Logo large for dark backgrounds

### Xenon Pharmaceuticals Logo large for dark backgrounds Download PNG (14.99 KB)

![Xenon Pharmaceuticals Logo large for dark backgrounds Download PNG (14.99 KB)](/img/orig/XENE_BIG.D-ef1b0cba.png)

### Xenon Pharmaceuticals Logo large for dark backgrounds Download SVG (5.15 KB)

![Xenon Pharmaceuticals Logo large for dark backgrounds Download SVG (5.15 KB)](/img/orig/XENE_BIG.D-a1ce5f5d.svg)

## Xenon Pharmaceuticals Logo icon format for dark backgrounds

### Xenon Pharmaceuticals Logo icon format for dark backgrounds Download PNG (24.72 KB)

![Xenon Pharmaceuticals Logo icon format for dark backgrounds Download PNG (24.72 KB)](/img/orig/XENE.D-6309c0cb.png)

### Xenon Pharmaceuticals Logo icon format for dark backgrounds Download SVG (2.24 KB)

![Xenon Pharmaceuticals Logo icon format for dark backgrounds Download SVG (2.24 KB)](/img/orig/XENE.D-70c9cb8d.svg)

## About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

1. Website domain: xenon-pharma.com
2. Employees: 149
3. Marketcap: $2.53 Billion USD


## Categories
- [x] ðŸ‡¨ðŸ‡¦ Canada
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
